Participación de las empresas

Hasta abril del 2017, el Medicines Patent Pool firmó acuerdos de licencia con AbbVie, Bristol-Myers Squibb, Gilead Sciences, the Johns Hopkins University, MSD (Merck & Co en los Estados Unidos y Canada), Pharco Pharmaceuticals, Roche, ViiV Healthcare, la Universidad de Liverpool y los Institutos Nacionales de la Salud de los Estados Unidos.

El MPP publicó su informe de priorización 2017 en febrero y seleccionó cinco compuestos para luchar contra el VIH y dos compuestos para luchar contra la hepatitis C. El MPP quiere conseguir acuerdos de licencia para estos tratamientos. En april de 2017, la fundación anunció una licencia para el ravidasvir, un compuesto para luchar contra la hepatitis C. El MPP también entró en negociaciones con Gilead Sciences para el bictegravir, una medicina para luchar contra el VIH.

El MPP también trabaja para conseguir de sublicencias a fabricantes de medicamentos genéricos y desarrolladores de  productos, de modo que puedan comenzar a fabricar medicamentos a un menor costo. Hasta el mayo de 2017, el MPP había celebrado acuerdos de sublicencias con 16 empresas: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Natco, Sandoz, Strides Arcolab, TB Alliance y Zydus Cadila.

El MPP espera continuar el diálogo con todos los titulares de patentes pertinentes y los fabricantes de medicamentos genéricos y asociaciones para el desarrollo de productos que reúnen los requisitos, a fin de alcanzar la meta de aumentar el acceso a medicamentos para las personas que viven con el VIH, la hepatitis C y la tuberculosis en los países en desarrollo.

En el siguiente cuadro, se resume el estado actual del compromiso con los titulares de patentes, y con los fabricantes de medicamentos genéricos y las asociaciones para el desarrollo de productos.

Participación de titulares de patente (en inglès)

Patent Holder 2017 2016 2015 2014 2013 2012 2011 2010
AbbVie Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014

Agreement for paediatrics signed in November 2014 In negotiations Not in negociations Not in negotiations

Reply received 26 January

Sent letter on 1 December
Boehringer-Ingelheim BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

BI announced the expansion of its non-enforcement policy to create greater access to nevirapine

In negotiations In negotiations In negotiations In negotiations In negotiations

Reply received 19 January

Sent letter on 1 December 
Bristol-Myers Squibb  Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013
Licence agreement for daclatasvir signed November 2015
Licence agreement for atazanavir signed in December 2013 Licence agreement for atazanavir signed in December 2013 In negotiations In negotiations

Reply received 26 January

Sent letter on 1 December
F. Hoffman-La Roche Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 In negotiations In negotiations Sent letter on 1 December
Gilead Sciences Licence agreement signed in July 2011 and July 2014. In negotiations for HIV medicine bictegravir. Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 and July 2014 Licence agreement signed in July 2011 Licence agreement signed in July 2011. Additional amendment made in July 2012 and November 2012 Licence agreement signed in July. Amendments made November 2011. In negotiationsReply received 14 February Sent letter on 1 December
Merck Sharp & Dohme (MSD) Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 Licence agreement for paediatrics signed in February 2015 In negotiations Not currently in negotiations Not currently in negotiations Not currently in negotiations. Reply received 28 January Sent letter on 1 December
Janssen Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015) Not currently in negotiations Not currently in negotiations Not currently in negotiations. J&J decision not to licence at this time Not currently in negotiations. Reply Received 31 January Sent letter on 1 December
Pharco Pharmaceuticals Licence and technology agreement for ravidasvir (RAV) in April 2017 N/A N/A N/A N/A N/A N/A N/A
University of Liverpool Collaborative Agreement to Develop HIV Nanomedicines in December 2015

 

 N/A  N/A  N/A  N/A  N/A  N/A N/A
 US National Institutes of Health Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir  Licence agreement signed in September 2010 for darunavir Licence agreement signed in September 2010 for darunavir

In negotiations

Licence agreement signed in September 2010 for darunavir

In negotiations

 Licence agreement signed in September 2010 for darunavir
ViiV Healthcare Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in March 2014 for dolutegravir

Licence agreement signed in February 2013 for abacavir

Licence agreement signed in February 2013 for abacavir In negotiations In negotiations Sent letter on 1 December

 

This page is also available in: Inglés, Francés